CERO THERAPEUTICS HOLDINGS, INC. (CERO) Form 424B3 — Jul 17, 2026
CERO Therapeutics filed a prospectus supplement to register 729,596,950 shares of common stock for resale, relating to a convertible note financing agreement. The filing updates the prospectus with details from a Form 8-K regarding a Second Amended and Restated Promissory Note entered into with SRX Global Inc. The company increased the maximum loan amount under the note to $2,085,200, which includes a recent funding of $671,600. This debt instrument carries a 10% annual interest rate and a 25% original issue discount, reflecting a high cost of capital for the company.
Key figures
- Debt Amount
- 2085200
- Interest Rate
- 10
- Maturity Date
- 2027-05-28
- Shares Offered
- 729596950
- Last bid price
- $0.0115
- Conversion discount
- 80% of lowest VWAP
- Conversion floor price
- $0.05
- Original issue discount
- 25%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.